Chondrocyte-based implant for the delivery of therapeutic agents
OwnerAvner Yayoninventor
Life of this patent
Estimating the term…
Abstract
The present invention relates in general to chondrocyte based explants and implants of genetically engineered chondrocytes and in particular, to the delivery of peptides, proteins and RNAi molecules to a mammalian subject using a genetically modified chondrocyte-based mass. In one embodiment the genetically modified chondrocyte-based mass is provided as a chondrocyte pellet.
Claims32
A cell mass comprising a plurality of genetically modified chondrocytes, wherein the genetically modified chondrocytes express a therapeutic agent.
(canceled)
-19. (canceled)
A method of transplanting to a subject in need of a therapeutic agent a cell mass comprising a plurality of genetically modified chondrocytes, the method comprising the steps of:
- a. isolating a cartilage explant;
- b. transducing cells of the explant to form genetically modified chondrocytes;
- and
- c. transplanting the genetically modified chondrocytes into a subject, wherein the genetically modified chondrocytes express the therapeutic agent.
(canceled)
A method of transplanting to a subject in need of a therapeutic agent an implant comprising genetically modified chondrocytes, wherein the genetically modified chondrocytes express the therapeutic agent, wherein said chondrocytes are derived from a source selected from articular cartilage, chondroprogenitor cells and mesenchymal progenitor cells (MPC).
Dependencies are inferred from the claim text.